Alteogen Signs $391 Million License Agreement with GSK Subsidiary Tesaro

Alteogen announced on January 20 that it has signed an exclusive license agreement with Tesaro, a subsidiary of GSK, for the development and commercialization of a subcutaneous (SC) formulation of dostarlimab utilizing the Hybrozyme technology-applied ALT-B4.

Under this agreement, Tesaro has secured exclusive rights to develop and commercialize a subcutaneous formulation of the PD-1 inhibitor dostarlimab using Alteogen's Hybrozyme technology-applied hyaluronidase, ALT-B4.

Alteogen's core competitive strength is its Hybrozyme platform-based recombinant human hyaluronidase (ALT-B4). This enzyme is essential for converting high-volume antibody drugs from intravenous (IV) to subcutaneous (SC) injection, and according to the company, it can reduce administration time from tens of minutes or several hours to just a few minutes, thereby improving both patient convenience and hospital operational efficiency.

Through this agreement, Alteogen will receive an upfront payment of 20 million dollars (approximately 29.5 billion won), and may receive up to 265 million dollars (approximately 391.5 billion won) in milestone payments upon achieving key development, regulatory, and sales milestones. Additionally, Alteogen will receive royalties based on product sales after commercialization. Alteogen will also be responsible for the clinical and commercial supply of ALT-B4.

Alteogen CEO Jeon Taeyeon stated, "We are very pleased to expand the application of our Hybrozyme technology in the oncology field through this collaboration with Tesaro," adding, "We look forward to the successful development and market launch of the subcutaneous formulation therapy."